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in Diabetic Cardiomyopathy
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Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL,
United States

Diabetic cardiomyopathy (DCM) or diabetes-induced cardiac dysfunction is a direct
consequence of uncontrolled metabolic syndrome and is widespread in US population
and worldwide. Despite of the heterogeneous and distinct features of DCM, the clinical
relevance of DCM is now becoming established. DCM progresses to pathological cardiac
remodeling with the higher risk of heart attack and subsequent heart failure in diabetic
patients. In this review, we emphasize lipid substrate quality and the phenotypic, metabolic, and biochemical stressors of DCM in the rodent and human pathophysiology. We
discuss lipoxygenase signaling in the inflammatory pathway with multiple contributing
and confounding factors leading to DCM. Additionally, emerging biochemical pathways
are emphasized to make progress toward therapeutic advancement to treat DCM.
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INTRODUCTION
Cardiovascular disease (CVD) is the primary cause of death including substantial people suffering
from obesity and type 2 diabetes. With an increased population of patients displaying metabolic
syndrome, there are 17.3 million deaths per year, and this number is expected to increase to more
than 23.6 million by 2030 (1, 2). Diabetes and obesity are primary metabolic triggers associated
with imbalanced energy [fatty acids (FAs)] intake, which is an inherent part of the modern lifestyle.
Obese people are often prone to or diagnosed with insulin resistance, pre-diabetes, impaired glucose
tolerance, or type 2 diabetes. According to current statistics, nearly 29 million individuals in US have
diabetes, and one in three adults has the pre-diabetic condition (3) and heart disease, and stroke is
leading cause of disability, morbidity, and death among people with accelerated or uncontrolled type
2 diabetes. CVD is associated with ~65% of deaths related to diabetes (4) and has an adverse effect on
left ventricle size, geometry, and function leading to diabetic cardiomyopathy (DCM).
Diabetic cardiomyopathy is a complex pathological as well as adaptive condition characterized
by dysfunctional effects on the left ventricle and is developed by a combination of several metabolic
disorders including prediabetes, hyperglycemia, insulin resistance (in type 2 diabetes), hypertension, and obesity (5). There are multiple factors and mechanisms including aging that aggravate
the pathology of DCM. However, in the current context of cardiomyopathy, DCM is defined by
presence of abnormal myocardial diastolic or systolic function in the presence of diabetes without
known hypertension or coronary artery disease (6). It has been categorized and presented in different manners as it includes features of left ventricular (LV) hypertrophy, myocardial fibrosis, and
myocardial energy dysregulation with differential degrees of myocardial biochemical, mechanical,
or structural dysfunction. Due to its multifactorial origin and distinct pathophysiology, there are
some controversies regarding the existence or non-existence of DCM. Clinically, DCM lacks classical features of a cardiomyopathy such as ventricular dilation and meaningful systolic dysfunction.
From metabolism perspective, DCM is a combination of molecular myocardial abnormalities
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that lead to the development of myocardial dysfunction with
co-existence of additional stressors such as obesity, hypertension, and coronary artery disease. In this review, we focus on the
etiology that aggravates DCM in clinical and pre-clinical settings.
We discuss pathophysiological and metabolic stressors that are
prime contributors to DCM. In order to focus on the development and advancement of therapeutic targets in the DCM field,
we asked three questions: (1) Do we need to treat the original
conditions or metabolic abnormalities of DCM in order to reduce
or prevent DCM and heart failure? (2) Do we need to develop
a pharmacological lifestyle or targeted aggressive metabolomics
approach to identify the biomarker signatures to treat DCM? (3)
Does a combination of (1) and (2) allow adequate control of the
original metabolic abnormality with focused treatment of DCM,
particularly in an aging population?

Zucker fatty (ZF) rats or leptin-deficient obese mice, showed a
depression in cardiac function (13, 14). However, a few studies
also reported the normal function of the heart in obese rodent
models (15, 16). As type of fat, duration, and dose consumed
impacts LV structure, function, and healing in the myocardial
infarction (MI)-induced model, the translational prospects of fat
intake and intervention studies should be used with caution. This
is exemplified by studies from Brainard and colleagues suggesting
that a high-fat diet in the form of lard or milk before and after
MI is insufficient to induce cardiac dysfunction, despite adiposity
and impaired glucose disposal (17). The study showed that the
signs of cardiac dysfunction are not visible in commonly used
mouse model [type 2 diabetic Lepr-deficient (db/db) mice or
streptozotocin (STZ)-treated wild-type mice] when subjected
to pressure overload. But the db/db model showed depressed
cardiac function when subjected to ischemia–reperfusion injury
in comparison with non-diabetic mice (17). By contrast, when
the obesity is superimposed on aging that is the trigger to develop
non-resolving inflammation post-MI. Recent study by Lopez
et al. highlighted that supplementation of n-6 FAs in aged mice
resulted in higher levels of 12-S-hydroxyeicosatetraenoic acids
(HETE) leading to an acute inflammatory response, further
delaying healing in MI (18). These results are similar to the findings that showed higher levels of 12-HETE in individuals with
stable angina (19). Studies of aging coupled with obesity have
shown that the n-6 enriched fat diet creates lipid metabolites that
are pro-inflammatory in nature (Figure 1). Aging mice fed a diet
enriched in linoleic acid showed increased neutrophils in the gut
and development of dysbiosis (20). Thus, these metabolites and
their action in disease pathology such as pressure overload, postMI healing, and overall cardiac remodeling will provide novel
tools for drug discovery and target identification.

METABOLIC STRESSORS FOR THE
DEVELOPMENT OF DCM
In order to understand the pathophysiology of DCM and its
etiology related to metabolic remodeling in the heart, we have
highlighted the major confounding causes below and summarized experimental rodent models used to understand the
dysregulation in the latter (Table 1), acknowledging that the
scope of this review does not allow us to discuss them all.

Obesity

Obesity is characterized by a low-grade chronic inflammation
phenotype with an excessive amount of body fat leading to heart
disease, diabetes, and high blood pressure. More than 34.9%, almost
78.6 million of US adults are obese (7). Obese and overweight
individuals are prone to insulin resistance and diabetes, accompanied frequently by LV eccentric or concentric hypertrophy (8).
Obesity is characterized on the basis of body mass index (BMI)
and has been proved to be associated with ventricular hypertrophy (9, 10). The association of obesity with systolic dysfunction
and with the prevalence of diabetes makes obesity a confounding
factor of DCM. The predicted body weight along with the excess
fat mass accounts for a rise in LV stroke volume and stroke works
due to accelerated heart rate. The Framingham study suggested
that a BMI >30 kg/m2 is positively correlated with increased LV
wall thickness, LV internal dimension in diastole, and LV mass
(11). A number of studies have shown that visceral adipose tissue
has higher levels of pro-inflammatory cytokines when associated with LV diastolic dysfunction (12). Studies performed on
the isolated hearts of genetic animal models of obesity, such as

Metabolic Syndrome, Diabetes, and Insulin
Resistance

Type 2 diabetes is defined as a metabolic syndrome with a
combination of insulin resistance and defective insulin secretion
by pancreatic β-cells. The Diabetes Control and Complications
Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) study was important in showing the role of
hyperglycemia in micro- and macro-vascular diabetes-mediated
complications (21, 22). Impaired insulin sensitivity results from
obesity and physical inactivity or genetic susceptibility (23, 24).
Currently, 39 million Americans are diabetic, predisposing them
to cardiovascular risk. Clinical data have demonstrated that diabetes is an independent risk factor for cardiovascular complications.

Table 1 | Metabolic dysregulations in diabetic cardiomyopathy.
Phenotypic parameters

STZ

OVE26

BB

NOD

KKAy

Alloxan

Akita

ob/ob

db/db

ZDF

Obesity
Diabetes
Hypertension

−
++
−

−
+
−

−
+
−

−
+
−

+
−
+

−
+
−

+
+
−

+
+
+/−

+
+
−

+
+
−

+, positive for metabolic pathology; ++, highly positive for metabolic pathology; −, negative for metabolic pathology.
STZ, streptozotocin; OVE26, beta-cell overexpression of calmodulin; BB, Biobreeding rat; NOD, non-obese diabetic; KKAy, yellow KK obese; ob/ob, leptin-deficient obese mice;
db/db, type 2 diabetic Lepr deficient; ZF/ZDF, Zucker fatty/Zucker diabetic fatty rats.
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In both men and women, diabetes has been observed to be one
of the primary causes of DCM and subsequent heart failure
over the last three decades (5, 25). The development of diabetes
with LV dysfunction was clinically evident 20 years earlier (26).
Many clinical studies have shown that more than 60% of diabetic
patients compared with well controlled subjects are diagnosed
with early and mild ventricular diastolic dysfunction (27, 28).
Studies have confirmed that DCM is not an unusual condition but
caused by low-grade non-resolving inflammation, uncontrolled
hyperglycemia (glucotoxicity), or hyperlipidemia (lipotoxicity).
These factors mainly contribute to metabolic syndrome, leading
to cardiac dysfunction and increasing the risk of MI or recurrent
MI (29). Glucotoxicity refers to uncontrolled hyperglycemia and
subsequent metabolic changes triggered by excess sugar or carbohydrate (30). Lipotoxicity is more complex and diverse because

of the essential nature of FAs, but excessive intake in aging may
lead to bone marrow adiposity and non-resolving inflammation
post-MI (31–35). The consequences of glucotoxicity or lipotoxicity considering the metabolic health and physical inactivity of a
diverse human population are key challenges in the prevention
and treatment of DCM (36). The Framingham Heart Study
showed that the frequency of heart failure is doubled in diabetic
men and quintupled in diabetic women in comparison with
age-matched control subjects. Clinical studies have shown that
diabetic subjects have a high risk of cardiac failure accompanied
with systolic dysfunction and LV hypertrophy (37, 38). Number
of surveys and studies have shown a higher prevalence of diastolic
dysfunction in diabetic patients (39, 40). Rodent and clinical
studies in diabetes setting have shown functional and structural
alterations in myocardium tissue. Studies performed in type 1
diabetic model, i.e., STZ-induced diabetic mouse, and rodents
with type 2 diabetes, i.e., ZF rats or db/db mice, have shown diastolic dysfunction (Table 2) (13, 41). In fat and fructose-feeding
studies, serum uric acid levels led to an increase in cardiac tissue
xanthine oxidase activity, which was temporally related to an
increase in body weight, fat mass, and insulin resistance without
changes in blood pressure, when these mice were subjected to
excess fat (46%) and fructose (17.5%) for 16 weeks. The high-fat
and fructose diet led to cardiomyocyte hypertrophy, oxidative
stress, interstitial fibrosis with impaired diastolic relaxation, and
macrophage polarization toward a pro-inflammatory phenotype
(42). Recent studies in many models have shown increases
in levels of the 12/15-lipoxygenase (LOX) pro-inflammatory
intermediate metabolite 12-HETE (43, 44). Insulin resistance is
the prime risk factor to initiate the defects in insulin signaling
pathways and glucose transport to cells. The resistance of the
body toward insulin results in increased production of insulin
in the pancreas leading to hyperinsulinemia (45). An association
between insulin resistance and heart failure was noted a century
ago and later traced to metabolic alteration (46).
Studies have shown that insulin resistance is a common factor in patients with non-ischemic cardiomyopathy compared
with control populations, which exclude pre-existing diabetes
patients (47). A study of 1,187 Swedish people showed that heart
failure could be anticipated in the patients with insulin resistance without any prior heart failure history, excluding all other
factors (48). Lack of insulin response can lead to inactivation of

Figure 1 | Overview of the metabolic and biochemical stressors in
diabetic cardiomyopathy (DCM). Metabolic stressor such as obesity,
diabetes, insulin resistance, aging, and circadian rhythms while the
biochemical stressors 12-(S)-HETE, cholesterol, ceramide, lipoproteins,
glucose trigger inflammation-mediated DCM.

Table 2 | Biochemical dysregulations in diabetic cardiomyopathy.
Functional and metabolic outcomes

Inflammation
Cardiac size
Cardiac function
Cardiac efficiency
Mitochondrial energetics
Lipid storage
Fatty acid oxidation
Glucose oxidation

Type 1 diabetes

Type 2 diabetes

STZ

OVE26

BB

NOD

Alloxan

Akita

ob/ob

db/db

ZDF

↑
=
↓
↓
↓
↑
↑
↓

↑
=
↓
=
↓
=
=
=

↑
=
↓
=
↓
=
=
=

↑
↑
↓
↓
=
↑
↑
=

↑
=
↓
↓
↓
=
=
=

↑
↓
↓
=
↓
=
↑
↓

↑
↑
↑/↓
↓
↓
↑
↑
↓

↑
↑
↓
↓
↓
↑
↑
↓

↑
↑
↓
=
=
↑
↑
↓

Up and down arrows indicate increase and decrease, respectively; =, indicates no change.
OVE26, beta-cell overexpression of calmodulin; NOD, non-obese diabetic; STZ, streptozotocin; ZF/ZDF, Zucker fatty/Zucker diabetic fatty rats.
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cellular pathways such as AKT inactivation, reduced nitric oxide
production, and increased apoptosis with alterations in myocardial structure (49–51). Insulin resistance is now considered to be
a cardiometabolic disorder predisposing people to both CVD and
diabetes. Metabolic risk factors in patients with insulin resistance
are atherogenic dyslipidemia, hypertension, glucose intolerance,
and a prothrombotic state (52). Further, McGavock et al., by
using proton magnetic resonance spectroscopy, have shown
that triglyceride accumulation occurs in human myocardium in
association with diabetes mellitus and insulin resistance, much
earlier than the symptoms of heart failure develop (53). Thus, the
accumulation of fat and abundance of FAs is associated with an
impaired cardiac efficiency and lipotoxicity.

which included patients with MI and angina pectoris, showed a
23–45% incidence of hypertension (64, 65, 166). Recent studies
suggest the involvement of 12/15-LOX in the murine models of
experimental hypertension by altering macrophage functions
(66). Patients with essential hypertension were observed to have
higher levels of 12-HETE and 12/15-LOX protein compared
with control subjects (67). A randomized, double-blinded, and
controlled clinical trial with patients having peripheral arterial
disease (75% hypertensive) showed that patients who consumed
a diet including 30 g of milled flaxseed (n-3-fatty acid-α-linolenic
acid) for 6 months displayed significant reductions in systolic
(−10 mm Hg) and diastolic (−7 mm Hg) blood pressure (68).
The plasma of FlaxPAD (Flaxseed for Peripheral Arterial Disease)
patients exhibited significant decreases in 5,6-, 8,9-, 11,12-, and
14,15-dihydroxyeicosatrienoic acid and 9,10- and 12,13-dihydroxyoctadecenoic acid versus controls. The study showed
that inhibition of soluble epoxide hydrolase contributed to the
antihypertensive effects and could be one of the pharmacological
targets (68).

Hypertension

Elevated blood pressure exerted on the vessel wall is commonly
referred to as hypertension. Hypertension is a well-known risk
factor for dilated hypertrophy, heart failure, and stroke. About
50% of ischemic strokes are caused by hypertension with a highrisk factor for hemorrhagic stroke. The risk ratio of MI doubles
when the diastolic pressure is 94 mm Hg and systolic pressure
is 140 mm Hg (54). Untreated hypertension is an add-on factor
for DCM, as it leads to the rapid advancement of mild subclinical DCM to the clinically visible diastolic dysfunction and then
later systolic dysfunction (55). Studies have shown that the
hypertensive-diabetic rats have greatest relative cardiac hypertrophy and increased interstitial fibrosis compared with only
diabetic or hypertensive animals. The combination of hypertension and diabetes mellitus led to myocardial degeneration similar
as observed in human patients (56). Increased blood pressure is
linked with sodium intake, hyperlipidemia, insulin resistance,
impaired glucose tolerance, obesity, pre-diabetes, and diabetes
and can lead to pulmonary edema and heart attack. The progression of DCM leads to activation of the renin-angiotensin system,
which leads to an increase in oxidative damage with cell apoptosis
and necrosis in the heart thereby increasing interstitial fibrosis
(57). The potent vasoconstrictor endothelin-1 (ET-1) isolated
from endothelial cells has inotropic, chemotactic, and mitogenic
properties, activating the renin-angiotensin-aldosterone system
to increase blood pressure. Many in vitro studies have highlighted
that high glucose activates ET-1, which mediates cardiomyocyte
hypertrophy via mitogen-activated protein kinase (MAPK)
activation (58). Genetic deletion or pharmacological inhibition of
ET-1 results in salt-sensitive hypertension (59). Depending upon
its presence in either medulla or cortex, the renal ET-1 has different effects on blood pressure. The upregulation of cortical ET-1
expression has been well demonstrated in various hypertensive
models via an increase in renal vascular resistance and a reduction in glomerular filtration rate (60, 61). Further, activation of
the glomerular ETA receptor leads to hypertension by enhancing
production of monocyte chemoattractant protein-1 and other
pro-inflammatory factors, sequestering macrophages and lymphocytes, thereby increasing sodium reabsorption (62). Clinically,
it has been observed that mortality of patients suffering from MI
is greater in hypertensive patients, as showed in the PROCAM
study (63). Hypertension, when it coexists with diabetes, doubles
the risk of cardiac failure. Other trials, 4S, CARE, and LIPID,
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BIOCHEMICAL STRESSORS FOR THE
DEVELOPMENT OF DCM
This review further discusses biochemical mechanisms such
inflammation, 12/15-LOX signaling, FA oxidation, and lipotoxicity that are directed toward increasing our understanding of novel
ways for the prevention and treatment of cardiomyopathy.

LOX Signaling and Inflammation

Inflammation is an essential biological process to restore normal
tissue homeostasis after injury. The state of inflammation is
mediated by upregulation of multiple signaling pathways, such
as NF-κB, c-Jun NH2-terminal kinase, or p38-MAPK associated
with insulin resistance, which have profound roles in diabetic
complications (69, 70). Thus, overactive inflammation is unifying
component of many chronic diseases eventually leading to heart
failure. Since in early 1950s, several reports validates that chronic
inflammation is key hallmark signature in congestive heart failure
pathology. Levine et al., in 1990, documented a positive correlation between TNF-α and chronic heart failure (71). Direct correlation between many chemokines/cytokines and heart failure
suggests large oxidative products, which are key regulators of the
inflammatory process, exerting both pro- and anti-inflammatory
effects (72, 73). The lipid-metabolizing enzymes, including
different members of the LOX family, are major players in the
pathogenesis of heart failure. LOXs are enzymes that metabolize
polyunsaturated FAs (74). The differential prostaglandins are produced by the cyclooxygenase pathway and leukotrienes through
the LOX pathway, with availability of arachidonic acid substrate
leading to overactive inflammation during the healing process in
heart failure pathology. Arachidonic acid serves as the substrate
for LOX pathway that facilitates interaction with 5-, 12-, and
15-LOX. Within the family of LOXs, 12- and 15-LOX (referred
as together 12/15-LOX) forms a subgroup of phylogenetically
closely related enzymes that are highly, but not exclusively,
expressed in distinct monocyte-derived cells (74). 12/15-LOX is
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Lipotoxicity

often referred to as “leukocyte-type” 12-LOX, and has orthologs
in other species such as human 15-LOX and rabbit 15-LOX-1 (75).
Murine and human 12/15-LOX differ in their enzymatic activity
and in their position during arachidonic acid oxygenation resulting in the predominant generation of 12-(S)-HETE by murine
12/15-LOX and 15-HETE by human 12/15-LOX (15-LOX-1),
respectively (76). The pro-inflammatory role of 12/15-LOX has
been evidenced in failing hearts (44, 77). Wen and colleagues
demonstrated that 12/15-LOX products, i.e., 12(S)-HpETE
(12(S)-hydroperoxyeicosatetraenoic acid) and 12(S)-HETE,
are pro-inflammatory in nature and stimulate TNF-α and IL-6
expression in macrophages as a particular effect of the 12/15-LOX
products. A recent report by Suzuki et al. demonstrated that the
TNF-α and collagen markers were elevated with increases in
12/15-LOX expression in the STZ-induced diabetic heart (44).
By contrast, 12/15-LOX knockout mice showed suppressed levels
of TNF-α and collagen markers with improved cardiac function.
These authors also demonstrated that administration of a 12/15LOX inhibitor (CDC) suppressed the TNF-α levels associated
with high blood glucose levels in vitro (44).

Altered FA utilization and intramyocardial lipid accumulation
are key major factors in the pathogenesis of DCM. The metabolic preference of the diabetic heart toward glucose leads to an
increase in FAs, which leads to lipid accumulation resulting in
lipotoxicity. Clinical studies suggest that congenital lipodystrophy, a rare disease causing accumulation of lipids in non-adipose
tissue, is one of the causes of premature cardiomyopathy (85). In
diabetic and obese animal models, accumulation of triglycerides
in cardiomyocytes is often associated with impaired contractile
function (86). Further, rat models of obesity have shown that
defects in the leptin receptor result in an excess of fat overload
in non-adipose tissues resulting in lipotoxicity (87). A study in
obese Zucker rats have shown that PPAR-α-regulated genes play
a crucial role in FA oxidation but become impaired in the failing
heart, suggesting that metabolic dysregulation due to triglyceride
overload and gene expression alteration leads to contractile
dysfunction. It has also been reported that intake of unsaturated
FAs increases low-density lipoprotein (LDL), triacylglycerols,
and Lp(a) lipoprotein, and decreases high-density lipoprotein
with a reduction in LDL cholesterol particle size, which leads
to alteration in serum lipid profiles, thereby doubling the risk
of CVD (88). Further, the consumption of FAs increases inflammation altering the prostaglandin balance. This impairment in
the activity of desaturase (the enzyme converting linoleic acid to
arachidonic acid and other n-6 polyunsaturated FAs) confers a
high-risk of CVD (89–91).

FA Oxidation

The beta-oxidation of FAs is the primary mechanism for the
heart to produce energy. Under resting conditions, FAs cover
more than 70% of the cardiac energy needs by meeting this
demand through the tricarboxylic acid cycle and electron
transport chain. The excess of FAs is stored in adipose tissue.
During obesity and diabetes, the adipose tissue increases in size
that overspills free FAs leading to imbalance between energy
demand and supply (78). An imbalance of FA oxidation or
glucose oxidation leads to changes in cardiac mitochondrial
metabolic energy that leads to ventricular dysfunction and to
a decrease in cardiac performance. The impaired FA oxidation
or increase in FA uptake in diabetes leads to an intramyocardial
lipid overload (79). Myocardial abundance triggers defects in
insulin signaling and activation of peroxisome proliferatoractivated receptor-α (PPAR-α)/PGC-1 (80). The changes in FA
oxidation lead to lipotoxicity and ceramide accumulation in
cardiac tissue. Wu et al. have demonstrated that the deletion
of the gene encoding aryl hydrocarbon nuclear translocator
(ARNT) in the liver/pancreas leads to a diabetic phenotype
with twofold increase in FA oxidation. The deletion of ARNT
leads to an increase in the expression of PPAR-α and its target
genes (81). FA oxidation is a major contributor of carbon
substrates to ATP generation in the adult heart. However, the
heart has a unique ability of metabolic flexibility and utilizes
glucose, lactate, ketones, and amino acids (82). The heart has
the capacity to selectively use substrate based on availability
and pathophysiological state. It is well documented that glucose
and lactate are preferred by the fetal heart; however, lipids
are the predominant fuel in the adult heart. Animal models
of cardiac hypertrophy are observed to switch their substrate
metabolism, recapitulating the “fetal metabolic profile” utilizing carbohydrates as primary energy sources (83, 84). Cardiac
hypertrophy models show the consistent appearance of fetal
gene expression, which is considered prime trigger in the
pathological remodeling of the heart.

Frontiers in Cardiovascular Medicine | www.frontiersin.org

Glucotoxicity

Dysregulation of myocardium FAs use for energy source results
into glucotoxicity in hyperglycemia setting developing progressive myocardial fibrosis due to glycosylation, cross-linking, and
accumulation of extracellular matrix proteins (92). There is a
reduction in glucose transporter expression, which inhibits
glucose translocation from plasma membrane to the cell in
DCM. During ischemia, PPAR’s inhibits insulin’s action that
reduces the rates of glycolysis and pyruvate oxidation resulting
in shutdown of glucose metabolism to the hexosamine biosynthesis pathway (93–95). The inappropriate hexosamine biosynthesis metabolism leads to the production of reactive oxygen
species (ROS) and the increased formation of intracellular
advanced glycosylation end-products (AGEs). AGEs and hexosamine biosynthesis impacts the sarco-endoplasmic reticulum
Ca2+-ATPase and the Ca2+ release channel, ryanodine receptor 2,
leading to abnormal cardiac relaxation and contractility (96, 97).
Wang et al. showed a novel role of active heparanase in modulating cardiac metabolism via cross talk between endothelial
cell and cardiomyocyte to increase lipoprotein lipase secretion
after hyperglycemia (98). The study showed that high glucose
is a common stimulus for latent heparanase secretion from
the endothelial cells and promotes its uptake into the cardiomyocyte (99). Presence of latent form of heparanase in the
cardiomyocyte leads to the significant shift in the expression of
apoptosis-targeted genes, providing an acute cardioprotective
effect indicating diversified roles of heparanase in DCM and
heart failure pathology (99).
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GENDER SPECIFICITY, CIRCADIAN
RHYTHM, AND AGING MODULATORS
IN DCM

advanced glycation end-products, inflammatory signaling, and
changes in many transcriptional regulators along with 12/15-LOX,
which contribute toward the pathogenesis as shown in Figure 2
(113). Being a multifactorial disease, the crosstalk between immune
cell dysregulation, cardiomyocytes, endothelial cells, and fibroblasts
leads to the impairment of several signaling pathways leading to the
etiology of DCM discussed above. The MAPK family is essential
for cardiac survival, and MAPK signaling impairment has been
well studied in diabetic tissue (114, 115). STZ-induced diabetic rats
have shown upregulated p-38-MAPK activity (116). The diabetic
myocardium mediates apoptosis via ASK1, a MAPKKK signaling
molecule (117). FoxO (forkhead box-containing protein, O subfamily-3, -4) proteins are major targets for the maintenance of cardiac
function and stress responsiveness by regulating cardiac growth,
insulin signaling, and glucose metabolism in the heart (118–120).
Also, several pathways including mammalian target of rapamycin,
microRNAs, Pim-1 (proviral integration site for moloney murine
leukemia virus-1), endoplasmic reticulum stress, and unfolded
protein responses are dysregulated in DCM (121).

Although gender-specific studies have shown that females tend to
develop cardiac complications 10–15 years later than men (100), it
has also been proven that women with diabetes and hypertension
have a greater risk of developing CVD (101, 102). Clinical reports
have also shown that if CVD presents at a younger age in women, it
is more detrimental (103). The female heart tolerates stress, such as
ischemic insults, better than the male heart. In diabetes, the estrogen in females may interact with certain risk factors, which may be
deleterious to overall cardiac function. A study published by Peters
and colleagues showed a sex-specific risk of stroke conferred by
diabetes. Meta-analysis conducted for 64 cohorts including 775,385
individuals who did not show any signs of cardiac problems at
baseline determined that 12,539 individuals experienced fatal or
non-fatal stroke events (104). The circadian clock allows the body
to adjust metabolic cycles according to the shift in day and night.
These circadian oscillations impact physiological parameters of
a cardiovascular function, thermoregulation, lipid, and glucose
metabolism. Studies have shown that circadian misalignment
accelerates diabetes due to disruption of glucose-stimulated insulin secretion and beta-cell loss (105). Two transcription factors,
CLOCK and BMAL1, transcriptionally control the circadian clock
by binding to E-boxes of target genes upon heterodimerization
(106, 107). In the heart, BMAL1 regulates substrate utilization,
FA and glucose metabolism, and the PI3K/AKT/GSK3β signaling
axis. The cardiomyocyte-specific knockout of BMAL1 leads to
age-onset cardiomyopathy, reducing lifespan with impaired FA
and glucose metabolism (108). Our group has shown that genetic
disruption of BMAL1 results in diastolic dysfunction exacerbating
extracellular matrix remodeling, with the increase in expression of
a pro-inflammatory gene profile signifying early cardiac aging in
mice (109). Aging, diabetes, and hypertension have similar effects
on heart dysfunction, resulting in LV hypertrophy and stiffness.
Aging leads to an increase in cardiovascular stiffness contributing
to the development of fibrosis. Fibrosis increases collagen crosslinking due to the formation of AGEs (110). Rodent studies have
shown that at 16 weeks of age, structural and functional changes
are observed in both the heart and kidney, in the Zucker diabetic
fatty model of type 2 diabetes. Aging is widely impacted by the
diverse intake of dietary ingredients (111). Both insulin resistance
and hyperglycemia can occur with an increase in n-6 FAs, which
further magnifies the inflammatory response in heart failure in
aging (112). Clinically, with advancing age, the risk to people
with the normal systolic function of having heart failure is 50%.
However, diastolic dysfunction occurrence is higher in women
with hypertensive heart disease and diabetes.

DEVELOPMENT OF NOVEL TARGETS
FOR DCM
Being a multifactorial disease; currently, there is no specific
therapy for DCM. Table 3 describes established rodent models
to study DCM for novel treatment. Since insulin resistance is
one of the leading causes of the pathogenesis of cardiomyopathy, insulin signaling is one of the targets. Anti-diabetic drugs,
such as metformin, act on the metabolic target AMPK and may
confer cardiovascular benefit (122, 123). Similarly, maintaining
a proper diet and exercise can reduce the risk of diabetes and
CVDs (124). Compounds modulating free FA metabolisms, such
as perhexiline, trimetazidine, ranolazine, and amiodarone, have
been shown to reduce lipotoxicity (125). The resveratrol-activated
NAD-dependent protein deacetylase Sirt1 is a potent target as
it plays a role in lowering blood glucose and increasing insulin
sensitivity (126). Cardiac excitation–contraction coupling and
insulin signaling dysregulation can also be improved by cellbased and genetic ablation therapy, which are among the robust
strategies for treating CVDs (127). With the emergence of potent
pro-inflammatory and anti-inflammatory roles of arachidonic
acid metabolites such as 20-HETE, 12-HETE, and soluble epoxide
hydrolase in diabetes and CVD (77, 128, 129), lipid mediators and
their enzymes are among the potent future therapeutic targets to
protect against the initiation and progression of DCM. The underlying concept “targeted or aggressive metabolomic” approach
used by West et al. to the targeted metabolic profiling of cardiac
tissue in dilative cardiomyopathy can be one the promising tool
to delineate the DCM in future (130). With the rapid evolvement
of the targeted metabolomics that aims to measure the endogenous metabolites in a cell or body fluid providing the functional
readout. All the changes in the functional reads outs, such as
shifts in the homeostasis of key lipids, carbohydrates, or amino
acids, are associated with genetic variants. The first genome-wide
association study with metabolomics (KORA study) using the
quantitative measurement of 363 metabolites in serum of 284
male participants (131). The study found an association of single

EMERGING MOLECULAR PATHWAYS
FOR DCM
Diabetic cardiomyopathy leads to structural and functional
changes in myocardium by activation of signaling pathways, i.e.,
altered calcium signaling, increased ROS, ceramides, hexosamines,
Frontiers in Cardiovascular Medicine | www.frontiersin.org
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Figure 2 | Integration of metabolic and fatty acids (FAs) metabolizing enzymes pathway in mitochondrial dysregulation, fibrotic hypertrophy,
and chronic inflammation.

Table 3 | Established rodent diabetic cardiomyopathy models for the development of novel therapy.
S. No

Model

Metabolic, biochemical, and functional outcomes

1

Streptozotocin

Lipotoxicity, hyperglycemia, diastolic and systolic dysfunction, hypertrophy,
inflammation, fibrosis, glucose and fatty acid (FA) oxidation, mitochondrial
dysfunction, oxidative stress, Ca2+ impairment

(32, 33, 35, 134–138)

2

Beta-cell overexpression of calmodulin

Reduced insulin levels, hyperglycemia and hyperlipidemia, impaired cardiac
function, hypertrophy, inflammation apoptosis, FA oxidation, mitochondrial
dysfunction, Ca2+ impairment

(98, 139–144)

3

Non-obese diabetic

Autoimmune diabetes, hyperglycemia, high cholesterol, diastolic and
systolic dysfunction, steatosis, immune dysregulation

4

Leptin-deficient obese mice

Leptin deficiency, appetite suppression hyperglycemia and hyperlipidemia,
diastolic dysfunction, hypertrophy, inflammation steatosis, apoptosis,
decreased glucose oxidation and increased FA oxidation, mitochondrial
dysfunction, Ca2+ impairment

(15, 41, 93, 135, 152–159)

5

Type 2 diabetic Lepr deficient

Hyperglycemia and hyperlipidemia, diastolic and systolic dysfunction,
hypertrophy, inflammation steatosis, apoptosis, decreased glucose
oxidation and increased FA oxidation, mitochondrial dysfunction, oxidative
stress, Ca2+ impairment

(13, 41, 147, 155, 158, 160–165)
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nucleotide polymorphisms with considerable differences in the
metabolic homeostasis. The study found four genetic variants in
genes coding for enzymes (FADS1, LIPC, SCAD, and MCAD)
where the corresponding metabolic phenotype (metabolite)
clearly matches the biochemical pathways in which these enzymes
are active. The study clearly links genetic polymorphisms induce
changes in the metabolic make-up of the human population
opening a whole new field for personalized health care based
on a combination of genotyping and metabolic characterization.
The adaptation of sedentary lifestyle and eating habits has led to
the increase in DCM about 5% of the global population (132). A
blinded randomized personally tailored dietary intervention with
consistent alterations to gut microbiota resulted in significantly
lower postprandial responses (133). Accurate personal dietary
recommendation using personal and microbiome features will be
valuable in lowering the risk of DCM and associated inflammatory, metabolic, and neoplastic multifactorial disorders and can
be effective clinical decision-making scheme.

and clinical models, it is possible to determine whether the
DCM is of a dilated, hypertrophy, non-compaction or restrictive
type, or of a combination of these. Whether the distinct target
is at the enzymatic (LOX), mitochondria centric, ion-channel
related, or defective chemokine-cytokine signaling level. Thus,
additional studies with the major emphasis on metabolic and
biochemical stressors in the advancement of heart function and
dysfunction will determine future treatment(s). Despite the high
mortality in diabetes patients due to heart failure, a number of
questions regarding what triggers DCM or amplifies progressive
cardiomyopathy remain unclear; therefore, urgent research on
novel therapies is needed to meet the demand of personalized
and precise medicine in the twenty-first century (165).
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